B2PRIME Group has significantly expanded its institutional liquidity architecture by securing additional Tier-1 prime broker lines and broadening relationships with Tier-1 banks. This upgrade allows B2PRIME to support larger counterparties and more complex trading models with customized liquidity streams tailored to client needs. The firm’s enhanced infrastructure improves liquidity quality, execution performance, and risk management, positioning it to serve sophisticated institutional clients at scale. Following strong growth in 2025, B2PRIME is now better equipped to offer competitive multi-asset liquidity solutions globally.
B2PRIME's institutional liquidity expansion is the subject, with Pluang's Financials sector offering context. As of Oct 13, 2026 22:41 WIB, 118 US Financials stocks were priced on Pluang, with 52 rising and 65 falling. Notable movers include FIGR at USD 27.35 down 3.90%, HUT at USD 81.98 down 3.82% with 93% of orders selling, and CLSK at USD 9.93 down 3.59% with 64% of orders buying.
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
Citigroup reported Q3 2026 earnings that exceeded analyst expectations, with EPS of $2.85 beating the $2.65 estimate and revenue of $23.8 billion slightly above forecasts. The bank's profit rose 40%, driven by exceptional fixed-income trading, invest...
State Street is set to report its Q3 2026 earnings with forecasts showing a 31.3% increase in earnings and 14% revenue growth, driven by strong net interest income and service fees. Despite record assets under management, higher operating and technol...
Restaurant Technologies, Inc. (RTI) released its 2026 Impact Report highlighting significant progress in sustainability and operational efficiency. In 2025, RTI recycled 393 million pounds of used cooking oil and delivered 719.4 million pounds of fre...
Over 60 companies are actively developing more than 65 medical marijuana therapies targeting conditions like chronic pain, neurological disorders, and cancer symptoms. Key drugs such as ZYN-002 and CardiolRx are in late-stage trials, with others in e...
